<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729207</url>
  </required_header>
  <id_info>
    <org_study_id>TS-TK-254-US0200</org_study_id>
    <nct_id>NCT02729207</nct_id>
  </id_info>
  <brief_title>Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo Controlled, Proof of Concept Study to Investigate the Safety and Efficacy of the Esflurbiprofen Hydrogel Patch in Treatment of Acute Pain Associated With Ankle Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teikoku Seiyaku Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teikoku Seiyaku Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and the efficacy of the Esflurbiprofen Hydrogel Patch will be assessed in&#xD;
      comparing with placebo in the treatment of acute pain due to ankle sprain&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to lack of patients number&#xD;
  </why_stopped>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 27, 2016</completion_date>
  <primary_completion_date type="Actual">December 21, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of intensity of pain difference after 48hr treatment (SPID48h)</measure>
    <time_frame>48hr after treatment starting</time_frame>
    <description>SPID48h will be compared between EFHP and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPID24h</measure>
    <time_frame>24hr after treatment starting</time_frame>
    <description>Sum of intensity (VAS) of pain difference after 24hr</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SPID72h</measure>
    <time_frame>72hr after treatment starting</time_frame>
    <description>Sum of intensity (VAS) of pain difference after 72hr was measured</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ankle Sprain</condition>
  <arm_group>
    <arm_group_label>Esflurbiprofen 1.5% Hydrogel Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One patch per 24hr for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo One patch per 24hr for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esflurbiprofen Hydrogel Patch</intervention_name>
    <description>One patch per day for 7 days</description>
    <arm_group_label>Esflurbiprofen 1.5% Hydrogel Patch</arm_group_label>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be a male or female aged 18 to 65 years, inclusive.&#xD;
&#xD;
          2. Subject must have a diagnosis of uncomplicated acute minor ankle sprain of Grade I or&#xD;
             II as defined by the AAOS criteria.&#xD;
&#xD;
          3. Ankle sprain must have occurred &lt;48 hours prior to Screening.&#xD;
&#xD;
          4. Subject must have a baseline self-evaluated pain score of &gt;50 mm on a 100 mm VAS while&#xD;
             bearing weight on the affected ankle.&#xD;
&#xD;
          5. Female subjects of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and be willing to use an acceptable form of birth control from the day of&#xD;
             the first dose administration to 30 days after the last administration of the study&#xD;
             product.&#xD;
&#xD;
          6. Subject must be willing to refrain from using any other pain medication (other than&#xD;
             allowed rescue medication) during their participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is a pregnant, breastfeeding, or lactating female.&#xD;
&#xD;
          2. Subject has an acute ankle sprain of Grade III as defined by AAOS criteria.&#xD;
&#xD;
          3. Subject has an ankle fracture as confirmed by X-ray.&#xD;
&#xD;
          4. Ankle sprain requires surgical treatment.&#xD;
&#xD;
          5. Subject has experienced recurrent sprains (â‰¥3 sprains of the same joint) or has&#xD;
             sprained the affected joint within the last 12 months.&#xD;
&#xD;
          6. Subject has taken analgesics other than NSAID(s) or acetaminophen for any purpose&#xD;
             within 7 days of Screening.&#xD;
&#xD;
          7. Subject has taken flurbiprofen or naproxen within 24 hours of Screening.&#xD;
&#xD;
          8. Ankle sprain is treated prior to Screening by ultrasound, physical therapy, or&#xD;
             acupuncture.&#xD;
&#xD;
          9. Subject has used immunomodulators or immunosuppressive therapies (e.g., interferon,&#xD;
             oral or parenteral corticosteroids, and cytotoxic drugs) within 4 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
         10. Subject has used any medicated topical agents (e.g., medicated creams or lotions) on&#xD;
             the affected ankle within 7 days prior to Screening.&#xD;
&#xD;
         11. Subject is currently using any other medications that, in the opinion of the&#xD;
             Investigator, may exacerbate or mask the anticipated side effects of NSAIDs or&#xD;
             interfere with the Investigator's ability to monitor for them (e.g., blood thinners or&#xD;
             proton-pump inhibitors).&#xD;
&#xD;
         12. Subject has non-intact or damaged skin in the area to be treated (e.g., eczema,&#xD;
             psoriasis, exudative dermatitis, infected lesion, burn, or wound).&#xD;
&#xD;
         13. Subject has a history of ulcers, GI bleeding, hypertension, edema, heart failure, or&#xD;
             CV disease.&#xD;
&#xD;
         14. Subject has asthma (except childhood asthma), urticaria, angioedema, or bronchospasm.&#xD;
&#xD;
             a.A subject is eligible for the study if they have had no symptoms of these conditions&#xD;
             that required medication in the 5 years prior to Screening.&#xD;
&#xD;
         15. Subject has a history of any chronic pain disorder.&#xD;
&#xD;
         16. Subject has coagulation defects.&#xD;
&#xD;
         17. Subject has a history of severe cardiac, renal, or hepatic impairment within 12 months&#xD;
             prior to Screening that, in the opinion of the Investigator, would interfere with the&#xD;
             outcome of the study.&#xD;
&#xD;
         18. Subject has a severe systemic disease (e.g., cancer or severe acute infection).&#xD;
&#xD;
         19. Subject has a known allergy or hypersensitivity to flurbiprofen, aspirin, other&#xD;
             NSAID(s), or any excipient in the IP.&#xD;
&#xD;
         20. Subject has any systemic or dermatologic disorder that, in the opinion of the&#xD;
             Investigator, will interfere with the study results or increase the risk of AEs.&#xD;
&#xD;
         21. Subject has a history of uncontrolled chronic or acute concomitant disease that, in&#xD;
             the Investigator's opinion, would contraindicate study participation or confound&#xD;
             interpretation of the results.&#xD;
&#xD;
         22. Subject has applied ice or compression to the affected ankle within 2 hours prior to&#xD;
             Screening.&#xD;
&#xD;
         23. Subject has a bilateral ankle injury.&#xD;
&#xD;
         24. Subject has an ipsilateral knee injury. In the opinion of the Investigator, are&#xD;
             unsuitable for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masaru Kaneko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL Clinical Pharmacology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSAID Patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Ankle Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

